Aravon injection serves as a neuroprotective agent in clinical practice, available in various strengths including 1.5 mg, 30 mg, and 60 mg formulations. The 20ml version is particularly common due to its dosing flexibility.
This medication has demonstrated efficacy in treating acute cerebral infarction and amyotrophic lateral sclerosis (ALS). Its mechanism involves neutralizing free radicals that contribute to oxidative stress and neuronal damage, making it a valuable neurological treatment.
Dosage varies based on the condition's severity and patient response. The 1.5 mg injection suits initial treatment or sensitive patients, while the 20ml vial (containing 60 mg) accommodates more intensive therapy. Severe cases may require the 60 mg formulation.
Most patients tolerate Aravon well, with common side effects including headache, dizziness, and nausea. However, serious hypersensitivity reactions like rashes or anaphylaxis may occur, necessitating careful patient monitoring.
Available in multiple formulations including 1.5 mg tablets, Aravon offers treatment flexibility. While it represents an important neuroprotective option, healthcare providers must remain alert to potential adverse effects to ensure safe and effective use in neurological disorders.
